KRAS and cancer: Collectively, these findings demonstrate that diverse, KRAS-mutant cancer cells undergo large-scale transcriptional changes during sustained ERK/MAPK inhibition, yet the transcriptional programs associated with terminal resistance are heterogenous and model-specific.